Thyroid Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Thyroid Cancer Market Outlook
Thelansis’s “Thyroid Cancer Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024
To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Thyroid Cancer treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
Thyroid
Cancer Overview
Thyroid
carcinomas are relatively uncommon tumors. They include disease types that
range from indolent behaviour, such as papillary carcinomas, to fulminant and
lethal anaplastic disease. It originates from 2 types of thyroid endocrine
cells; Follicular thyroid and parafollicular cells. This accounts for >90%
of thyroid malignancies and including papillary thyroid cancer (PTC),
follicular thyroid cancer (FTC), poorly differentiated thyroid cancer (PDTC),
and anaplastic thyroid cancer (ATC). Of note, PTC and FTC are classified as
differentiated thyroid cancer (DTC). There are two classical signalling
pathways, the MAPK and the PI3K-AKT pathways. Both pathways are coupled to the
receptor tyrosine kinase (RTK) at the cell membrane, which transduces an
extracellular growth stimulus that prompts downstream intracellular signalling.
The MAPK pathway has a fundamental role in regulating cell proliferation,
differentiation, apoptosis, and survival and has been linked to tumorigenesis
when disrupted. Once RTK is activated by an extracellular signal, downstream
activation of RAS, followed by BRAF, MEK, and then ERK occurs. ERK enters the
nucleus to induce tumour-promoting genes and downregulate tumor suppressor
genes and thyroid iodide-handling genes.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment